REGENXBIO Inc.
REGENXBIO Inc. (NASDAQ: RGNX) is trading at $7.25, about ₹696 at today's USD/INR rate, as of 25 Sep 2026, 1:40 PM ET, up 0.14% today. Indian residents can buy REGENXBIO from India on Paasa under the RBI's Liberalised Remittance Scheme.
Quote
Today's low
$7.16
Today's high
$7.67
52 week low
$5.46
52 week high
$16.19
RGNX opened at $7.53, closed previously at $7.24, and has traded between $5.46 and $16.19 over the past 52 weeks.
About
REGENXBIO Inc. is a biotechnology company operating in the clinical stage, dedicated to developing gene therapy candidates. These therapies are designed to introduce genes into cells, aiming either to rectify genetic deficiencies or to stimulate the body's own cells to produce therapeutic proteins or antibodies to combat diseases. Central to its therapeutic development is the proprietary NAV Technology Platform, an adeno-associated virus-based gene delivery system. The company's primary investigational asset, RGX-314, is currently in Phase III clinical trials for treating wet age-related macular degeneration. Its pipeline also includes RGX-121 and RGX-111, both in Phase I/II trials for mucopolysaccharidosis type II and type I, respectively; RGX-181, which is in preclinical development for late-infantile neuronal ceroid lipofuscinosis type II disease; RGX-202, undergoing Phase I/II evaluation for Duchenne muscular dystrophy; and RGX-381, at the preclinical stage for addressing the ocular manifestations of CLN2 disease. In addition to its internal programs, REGENXBIO Inc. licenses its NAV Technology Platform to other biotech and pharmaceutical enterprises. It also maintains a collaborative and licensing agreement with Neurimmune AG for the advancement of innovative gene therapies. Founded in 2008, REGENXBIO Inc. maintains its headquarters in Rockville, Maryland.
Key statistics
Avg. volume
1.83M
Market cap
$374.81M
P/E Ratio
-1.91
Price-to-sales ratio
2.15
Enterprise value
$407.27M
Free cash flow yield
-66.61%
Debt-to-equity ratio
0.96
Return on equity
-220.07%
ROIC
-52.72%
Beta
0.93
Dividend yield
0.00%
Last dividend
$0.00
Financial overview
Revenue
$170.44M
Earnings per share
-$3.76
Free cash flow
-$126.38M
Net profit margin
-112.58%
Gross margin
54.22%
EBITDA
-$133.25M
Revenue growth
104.54%
Similar securities
This is not an investment recommendation
How to buy REGENXBIO from India
Indian residents can buy REGENXBIO shares through Paasa in four steps. Funds leave India under the RBI's Liberalised Remittance Scheme and the shares are held in your own name with Interactive Brokers.
Open a Paasa account
Complete digital KYC with your PAN, Aadhaar and address proof. Your brokerage account is opened in your own name with Interactive Brokers.
Add funds under LRS
Transfer INR from your Indian bank account. Your bank reports the remittance under the RBI's Liberalised Remittance Scheme and converts it to US dollars.
Search for REGENXBIO and place an order
Find REGENXBIO by name or by its ticker, RGNX, and choose an order type. You can buy by amount or by quantity — fractional shares mean there is no minimum trade size. REGENXBIO trades 7:00 pm – 1:30 am IST; orders can only execute during that window.
Track holdings and download tax reports
Follow your REGENXBIO position in USD and INR. REGENXBIO pays no dividend today, so your filing is the capital-gains statement plus the Schedule FA holding line.
Read the full guide: how to invest in REGENXBIO from India
Trading and taxes when buying REGENXBIO from India
Trading and limits
- Trading hours
- 9:30 am – 4:00 pm ET
- LRS limit
- $250,000Per financial year, under the RBI's Liberalised Remittance Scheme.
Tax for Indian residents
- TCS on remittance
- 20%Collected by your bank on LRS remittances above ₹10 lakh in a financial year. The TCS is adjustable against your income-tax liability.Adjusting TCS against your tax
- Capital gains in India
- 12.5% or slab rateGains on shares held for more than 24 months are long-term and taxed at 12.5%. Gains on shares held for 24 months or less are short-term and taxed at your income-tax slab rate.Capital gains explained
- Dividends
- NoneREGENXBIO does not currently pay a dividend. If it starts, dividends are taxed at your slab rate in India.Dividend tax explained
- US estate tax
- May applyUS-situs assets such as US-listed shares can be exposed to US estate tax for non-US persons.US estate tax calculator
Custody. Shares are held in your own name at Interactive Brokers LLC and are SIPC-insured up to $500,000 in total, including $250,000 for cash.
FAQs
Can Indian residents buy REGENXBIO stock?
Yes. REGENXBIO (RGNX) has been listed on NASDAQ since 2015, in the Biotechnology industry, and Indian residents can buy it through Paasa. You fund the account from your Indian bank under the RBI's Liberalised Remittance Scheme and the money is converted to US dollars. Shares are held in your own name at Interactive Brokers LLC and are SIPC-insured up to $500,000 in total, including $250,000 for cash.
How much does one REGENXBIO share cost in rupees?
One REGENXBIO share is $7.25 — about ₹696 at a USD/INR rate of 96.02 on 24 Sep 2026. Both the REGENXBIO price and the rupee rate move during the day, so the rupee cost changes with them.
What are the LRS and TCS rules for buying REGENXBIO from India?
Remit up to $250,000 per financial year under the RBI's Liberalised Remittance Scheme (LRS). Banks collect 20% tax at source on LRS remittances above ₹10 lakh in a financial year; the TCS is adjustable against your income-tax liability. FX and the LRS declaration are handled by your bank when you fund your account.
Can I buy whole shares of REGENXBIO?
Yes. One REGENXBIO share is $7.25, and you can buy as many whole shares as you like. You can also buy by amount rather than by quantity: there is no minimum trade size, and Paasa supports fractional investing in REGENXBIO.
How are gains on REGENXBIO shares taxed in India?
The US does not levy capital gains tax on shares for Indian residents, so the tax is an India-side one. Gains on shares held for more than 24 months are long-term and taxed at 12.5%. Gains on shares held for 24 months or less are short-term and taxed at your income-tax slab rate. The gain is computed in rupees using the USD/INR rate on the purchase and the sale date, so the rupee move counts alongside the REGENXBIO price. Paasa issues a capital-gains statement for your return.
Does REGENXBIO pay a dividend?
No. REGENXBIO does not currently pay a dividend, so holding it produces no dividend income to declare in India. If it starts paying one, the Indian treatment is the usual one — dividends are taxed at your slab rate in India — and Paasa's dividend report would show the gross amount and any tax withheld.
When can I trade REGENXBIO from India?
NASDAQ trades 7:00 pm – 1:30 am IST in Indian time, so the close lands after midnight. The window shifts to 8:00 pm – 2:30 am IST when the US is on standard time. Orders can only execute during that window.
Is there estate or inheritance tax on REGENXBIO shares held from India?
US-situs assets such as US-listed shares can be exposed to US estate tax for non-US persons. It applies to your overall holdings in that jurisdiction rather than to any one position. Paasa's US estate tax calculator shows the exposure for a given portfolio value.
Do I have to declare REGENXBIO shares in my Indian tax return?
Yes. Foreign shares held on 31 March must be reported in Schedule FA of your Indian income-tax return. Paasa gives you a Schedule FA-ready statement listing your REGENXBIO holding, its cost and its closing value.
How do I sell REGENXBIO and bring the money back to India?
You sell during market hours (7:00 pm – 1:30 am IST) and the proceeds settle in USD in your Paasa account. From there you can hold the balance, reinvest, or repatriate. Funds can be withdrawn in any currency to any bank account in your own name. Whether the sale is short- or long-term is decided by the 24-month holding period.